Adam Jonathan Savitz MD
Assistant Attending Psychiatrist, NewYork-Presbyterian Hospital. Clinical Assistant Professor of Psychiatry (Courtesy), Weill Cornell Medical College, Cornell University.
Join to View Full Profile
21 Bloomingdale RdWhite Plains, NY 10605
Phone+1 914-997-4394
Fax+1 914-682-6906
Dr. Savitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1995 - 1998
David Geffen School of Medicine at UCLAClass of 1994
Certifications & Licensure
NY State Medical License 2001 - 2026
Clinical Trials
- Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia Start of enrollment: 2005 Sep 01
Publications & Presentations
PubMed
- 2 citationsTowards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decad...William P Horan, Amir Kalali, Stephen K Brannan, Wayne Drevets, Matthew Leoni
Schizophrenia Bulletin. 2025-03-14 - Response to Commentaries.William P Horan, Amir Kalali, Stephen K Brannan, Wayne Drevets, Atul Mahableshwarkar
Schizophrenia Bulletin. 2025-03-14 - Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.Sofie Mesens, Iva Kezic, Peter Van Der Ark, Mila Etropolski, Gahan Pandina
Molecular Psychiatry. 2024-12-11
Journal Articles
- The Open Translational Science in Schizophrenia (OPTICS) Project: An Open-Science Project Bringing Together Janssen Clinical Trial and NIMH DataEva C Guinan, Joseph S Ross, Adam J Savitz, Nature
Press Mentions
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of NeuropsychopharmacologyDecember 8th, 2022- Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderJuly 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
